Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07473713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary completion date: Mar 2028 to Mar 1, 2028 · Completion date: May 2028 to May 1, 2028 · Start date: Mar 2026 to Apr 15, 2026 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Mar 2028 to Mar 1, 2028
    • Completion date: May 2028 to May 1, 2028
    • Start date: Mar 2026 to Apr 15, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug
Trial Details
NCT Number NCT07473713
Lead Sponsor Tufts Medical Center
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Osteopenia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov